Vaccine immunology

Vaccines: Sixth Edition

Volumn , Issue , 2012, Pages 14-32

  Siegrist, Claire Anne ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902071102     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0090-5.00004-5     Document Type: Chapter

References (231)

1. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
2. Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327:291-295.
3. Palucka K., Banchereau J., Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010, 33:464-478.
4. Gatto D., Brink R. The germinal center reaction. J Allergy Clin Immunol 2010, 126:898-909.
5. Elgueta R., de Vries V.C., Noelle R.J. The immortality of humoral immunity. Immunol Rev 2010, 236:139-150.
6. Amanna I.J., Slifka M.K. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010, 236:125-138.
7. Pichichero M.E. Booster vaccinations: can immunologic memory outpace disease pathogenesis?. Pediatrics 2009, 124:1633-1641.
8. Duthie M.S., Windish H.P., Fox C.B., et al. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011, 239:178-196.
9. Sallusto F., Lanzavecchia A., Araki K., et al. From vaccines to memory and back. Immunity 2010, 33:451-463.
10. Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009, 9:185-194.
11. Cooper N.R., Nemerow G.R. The role of antibody and complement in the control of viral infections. J Invest Dermatol 1984, 83(1 suppl):121s-127s.
12. Lin Y., Slight S.R., Khader S.A. Th17 cytokines and vaccine-induced immunity. Semin Immunopathol 2010, 32:79-90.
13. Sakaguchi S., Miyara M., Costantino C.M., et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
14. Igietseme J.U., Eko F.O., He Q., et al. Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines 2004, 3:23-34.
15. Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr Res 2003, 338:2539-2547.
16. Lindberg A.A. Polyosides (encapsulated bacteria). C R Acad Sci III 1999, 322:925-932.
17. Lockhart S. Conjugate vaccines. Expert Rev Vaccines 2003, 2:633-648.
18. Casadevall A. The methodology for determining the efficacy of antibody-mediated immunity. J Immunol Methods 2004, 291:1-10.
19. Trotter C.L., McVernon J., Ramsay M.E., et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 2008, 26:4434-4445.
20. Kagina B.M., Abel B., Scriba T.J., et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 2010, 182:1073-1079.
21. Giuliano M., Mastrantonio P., Giammanco A., et al. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatr 1998, 132:983-988.
22. Salmaso S., Mastrantonio P., Tozzi A.E. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001, 108:E81. Stage III Working Group, and the, doi:10.1542/peds.108.5.e81.
23. Ausiello C.M., Lande R., Urbani F., et al. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J Infect Dis 2000, 181:1989-1995.
24. Ausiello C.M., Lande R., Urbani F., et al. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect Immun 1999, 67:4064-4071.
25. Kurubi J., Vince J., Ripa P., et al. Immune response to measles vaccine in 6 month old infants in Papua New Guinea. Trop Med Int Health 2009, 14:167-173.
26. Gans H.A., Yasukawa L.L., Zhang C.Z., et al. Effects of interleukin-12 and interleukin-15 on measles-specific T-cell responses in vaccinated infants. Viral Immunol 2008, 21:163-172.
27. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
28. Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327:291-295.
29. Palucka K., Banchereau J., Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010, 33:464-478.
30. Palm N.W., Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009, 227:221-233.
31. Querec T., Bennouna S., Alkan S., et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006, 203:413-424.
32. Hong Kong Measles Vaccine Committee Comparative trial of live attenuated measles vaccine in Hong Kong by intramuscular and intradermal injection. Bull World Health Organ 1967, 36:375-384.
33. Prausnitz M.R., Mikszta J.A., Cormier M., et al. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009, 333:369-393.
34. de Lalla F., Rinaldi E., Santoro D., et al. Immune response to hepatitis B vaccine given at different injection sites and by different routes: a controlled randomized study. Eur J Epidemiol 1988, 4:256-258.
35. Mutsch M., Zhou W., Rhodes P., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350:896-903.
36. Spreafico R., Ricciardi-Castagnoli P., Mortellaro A. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur J Immunol 2010, 40:638-642.
37. Meier S., Bel M., L'Huillier A., et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 2011, 29:3548-3557.
38. Pierce S.K., Liu W. The tipping points in the initiation of B cell signalling: how small changes make big differences. Nat Rev Immunol 2010, 10:767-777.
39. Goodnow C.C., Vinuesa C.G., Randall K.L., et al. Control systems and decision making for antibody production. Nat Immunol 2010, 11:681-688.
40. Reif K., Ekland E.H., Ohl L., et al. Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature 2002, 416:94-99.
41. MacLennan I.C., Toellner K.M., Cunningham A.F., et al. Extrafollicular antibody responses. Immunol Rev 2003, 194:8-18.
42. Deenick E.K., Hasbold J., Hodgkin P.D. Decision criteria for resolving isotype switching conflicts by B cells. Eur J Immunol 2005, 35:2949-2955.
43. Gatto D., Brink R. The germinal center reaction. J Allergy Clin Immunol 2010, 126:898-909.
44. Linterman M.A., Vinuesa C.G. T follicular helper cells during immunity and tolerance. Prog Mol Biol Transl Sci 2010, 92:207-248.
45. Crotty S. Follicular helper CD4 T cells (T(FH)). Annu Rev Immunol 2011, 29:621-663.
46. Flehmig B., Staedele H., Xueref C., et al. Early appearance of neutralizing antibodies after vaccination with an inactivated hepatitis A vaccine. J Infect 1997, 35:37-40.
47. Lucas A.H., Reason D.C. Polysaccharide vaccines as probes of antibody repertoires in man. Immunol Rev 1999, 171:89-104.
48. Zhou J., Lottenbach K.R., Barenkamp S.J., et al. Somatic hypermutation and diverse immunoglobulin gene usage in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 6B. Infect Immun 2004, 72:3505-3514.
49. Vinuesa C.G., Sze D.M., Cook M.C., et al. Recirculating and germinal center B cells differentiate into cells responsive to polysaccharide antigens. Eur J Immunol 2003, 33:297-305.
50. Weill J.C., Weller S., Reynaud C.A. Human marginal zone B cells. Annu Rev Immunol 2009, 27:267-285.
51. Zandvoort A., Timens W. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin Exp Immunol 2002, 130:4-11.
52. Timens W., Boes A., Rozeboom-Uiterwijk T., et al. Immaturity of the human splenic marginal zone in infancy: possible contribution to the deficient infant immune response. J Immunol 1989, 143:3200-3206.
53. Southern J., Deane S., Ashton L., et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 2004, 11:1100-1104.
54. Pollard A.J., Perrett K.P., Beverley P.C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009, 9:213-220.
55. Russell F.M., Carapetis J.R., Balloch A., et al. Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age: a randomized controlled trial. Vaccine 2010, 28:3341-3349.
56. Torling J., Hedlund J., Konradsen H.B., et al. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003, 22:96-103.
57. Baxter D. Vaccine responsiveness in premature infants. Hum Vaccin 2010, 6:506-511.
58. Lindberg A.A. Glycoprotein conjugate vaccines. Vaccine 1999, 17(suppl 2):S28-S36.
59. Baraldo K., Mori E., Bartoloni A., et al. Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein. Infect Immun 2005, 73:5835-5841.
60. Insel R.A. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann N Y Acad Sci 1995, 754:35-47.
61. Dagan R., Poolman J., Siegrist C.A. Glycoconjugate vaccines and immune interference: a review. Vaccine 2010, 28:5513-5523.
62. Bixler G.S., Eby R., Dermody K.M., et al. Synthetic peptide representing a T-cell epitope of CRM197 substitutes as carrier molecule in a Haemophilus influenzae type B (Hib) conjugate vaccine. Adv Exp Med Biol 1989, 251:175-180.
63. Benhamou E., Courouce A.M., Jungers P., et al. Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 1984, 21:143-147.
64. Centers for Disease Control and Prevention Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001, 50(RR-5):1-43.
65. Dormitzer P.R., Galli G., Castellino F., et al. Influenza vaccine immunology. Immunol Rev 2011, 239:167-177.
66. Kracker S., Durandy A. Insights into the B cell specific process of immunoglobulin class switch recombination [published online ahead of print February 13, 2011]. Immunol Lett 2011, 138:97-103. doi:10.1016/j.imlet.2011.02.004.
67. Anttila M., Eskola J., Ahman H., et al. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 1999, 17:1970-1977.
68. Siegrist C.A., Pihlgren M., Tougne C., et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 2004, 23:615-622.
69. Poland G.A., Ovsyannikova I.G., Jacobson R.M. Application of pharmacogenomics to vaccines. Pharmacogenomics 2009, 10:837-852.
70. Sette A., Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010, 33:530-541.
71. Pulendran B., Li S., Nakaya H.I. Systems vaccinology. Immunity 2010, 33:516-529.
72. Romanowski B., Schwarz T.F., Ferguson L.M., et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: Results from a randomized study [published online ahead of print December 1, 2011]. Hum Vaccin 2011, 7(12).
73. Krajden M., Cook D., Yu A., et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol 2011, 18:418-423.
74. Elgueta R., de Vries V.C., Noelle R.J. The immortality of humoral immunity. Immunol Rev 2010, 236:139-150.
75. Amanna I.J., Slifka M.K. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010, 236:125-138.
76. Winter O., Moser K., Mohr E., et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood 2010, 116:1867-1875.
77. Chu V.T., Frohlich A., Steinhauser G., et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol 2011, 12:151-159.
78. Honorati M.C., Palareti A., Dolzani P., et al. A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B. Clin Exp Immunol 1999, 116:121-126.
79. Van Herck K., Beutels P., Van Damme P., et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 2000, 60:1-7.
80. David M.P., Van Herck K., Hardt K., et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009, 115(3 suppl):S1-S6.
81. Fraser C., Tomassini J.E., Xi L., et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 2007, 25:4324-4333.
82. Bock H.L., Loscher T., Scheiermann N., et al. Accelerated schedule for hepatitis B immunization. J Travel Med 1995, 2:213-217.
83. Nothdurft H.D., Dietrich M., Zuckerman J.N., et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine 2002, 20:1157-1162.
84. Kurosaki T., Aiba Y., Kometani K., et al. Unique properties of memory B cells of different isotypes. Immunol Rev 2010, 237:104-116.
85. Good-Jacobson K.L., Shlomchik M.J. Plasticity and heterogeneity in the generation of memory B cells and long-lived plasma cells: the influence of germinal center interactions and dynamics. J Immunol 2010, 185:3117-3125.
86. Pichichero M.E., Voloshen T., Passador S. Kinetics of booster responses to Haemophilus influenzae type B conjugate after combined diphtheria-tetanus-acellular pertussis-Haemophilus influenzae type b vaccination in infants. Pediatr Infect Dis J 1999, 18:1106-1108.
87. Brown S.E., Howard C.R., Zuckerman A.J., et al. Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides. Lancet 1984, 2:184-187.
88. Ekstrom N., Ahman H., Verho J., et al. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun 2005, 73:369-377.
89. Cassidy W.M., Watson B., Ioli V.A., et al. A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics 2001, 107:626-631.
90. Goldblatt D., Vaz A.R., Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998, 177:1112-1115.
91. Zanetti A.R., Mariano A., Romano L., et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005, 366:1379-1384.
92. Duval B., Gilca V., Boulianne N., et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J 2005, 24:213-218.
93. Ahman H., Kayhty H., Vuorela A., et al. Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. Vaccine 1999, 17:2726-2732.
94. Borrow R., Goldblatt D., Finn A., et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect Immun 2003, 71:5549-5555.
95. Hendrikx L.H., Berbers G.A., Veenhoven R.H., et al. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. Vaccine 2009, 27:6530-6536.
96. Blum M.D., Dagan R., Mendelman P.M., et al. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine 2000, 18:2359-2367.
97. Huebner R.E., Mbelle N., Forrest B., et al. Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine. Vaccine 2004, 22:2696-2700.
98. Gray D., Skarvall H. B-cell memory is short-lived in the absence of antigen. Nature 1988, 336:70-73.
99. Crotty S., Felgner P., Davies H., et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003, 171:4969-4973.
100. Maruyama M., Lam K.P., Rajewsky K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature 2000, 407:636-642.
101. Bernasconi N.L., Traggiai E., Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-2202.
102. DiLillo D.J., Hamaguchi Y., Ueda Y., et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008, 180:361-371.
103. Bialek S.R., Bower W.A., Novak R., et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008, 27:881-885.
104. Posfay-Barbe K.M., Kobela M., Sottas C., et al. Frequent failure of adolescent booster responses to tetanus toxoid despite infant immunization: waning of infancy-induced immune memory?. Vaccine 2010, 28:4356-4361.
105. Trotter C.L., Andrews N.J., Kaczmarski E.B., et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004, 364:365-367.
106. Pichichero M.E. Booster vaccinations: can immunologic memory outpace disease pathogenesis?. Pediatrics 2009, 124:1633-1641.
107. Golaz A., Hardy I.R., Glushkevich T.G., et al. Evaluation of a single dose of diphtheria-tetanus toxoids among adults in Odessa, Ukraine, 1995: immunogenicity and adverse reactions. J Infect Dis 2000, 181(suppl 1):S203-S207.
108. Young B.W., Lee S.S., Lim W.L., et al. The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. J Viral Hepat 2003, 10:23-30.
109. Lin Y.C., Chang M.H., Ni Y.H., et al. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003, 187:134-138.
110. Whittle H.C., Maine N., Pilkington J., et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995, 345:1089-1092.
111. Makela P.H., Kayhty H., Leino T., et al. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003, 22:287-292.
112. Weinberg G.A., Einhorn M.S., Lenoir A.A., et al. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. J Pediatr 1987, 111:22-27.
113. McVernon J., Johnson P.D., Pollard A.J., et al. Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch Dis Child 2003, 88:379-383.
114. Lee Y.C., Kelly D.F., Yu L.M., et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis 2008, 46:186-192.
115. Ramsay M.E., McVernon J., Andrews N.J., et al. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003, 188:481-485.
116. McVernon J., Andrews N., Slack M.P., et al. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003, 361:1521-1523.
117. Richmond P., Borrow R., Miller E., et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999, 179:1569-1572.
118. Lee G.M., Lebaron C., Murphy T.V., et al. Pertussis in adolescents and adults: should we vaccinate?. Pediatrics 2005, 115:1675-1684.
119. Abbink F., Buisman A.M., Doornbos G., et al. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis 2005, 191:990-999.
120. Davidkin I., Peltola H., Leinikki P., et al. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination: a 15-year follow-up in Finland. Vaccine 2000, 18:3106-3112.
121. Dayan G.H., Quinlisk M.P., Parker A.A., et al. Recent resurgence of mumps in the United States. N Engl J Med 2008, 358:1580-1589.
122. Day P.M., Kines R.C., Thompson C.D., et al. In mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 2010, 8:260-270.
123. Randolph G.J., Angeli V., Swartz M.A. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 2005, 5:617-628.
124. Groothuis T.A., Griekspoor A.C., Neijssen J.J., et al. MHC class I alleles and their exploration of the antigen-processing machinery. Immunol Rev 2005, 207:60-76.
125. Shastri N., Cardinaud S., Schwab S.R., et al. All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol Rev 2005, 207:31-41.
126. Jutras I., Desjardins M. Phagocytosis: at the crossroads of innate and adaptive immunity. Annu Rev Cell Dev Biol 2005, 21:511-527.
127. Kapsenberg M.L. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003, 3:984-993.
128. Krogsgaard M., Davis M.M. How T cells "see" antigen. Nat Immunol 2005, 6:239-245.
129. + T cell differentiation, anergy and memory with implications for vaccines. Trends Mol Med 2010, 16:478-491.
130. Stetson D.B., Voehringer D., Grogan J.L., et al. Th2 cells: orchestrating barrier immunity. Adv Immunol 2004, 83:163-189.
131. O'Garra A., Robinson D. Development and function of T helper 1 cells. Adv Immunol 2004, 83:133-162.
132. Vinuesa C.G., Tangye S.G., Moser B., et al. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005, 5:853-865.
133. Swain S.L. CD4 T cell development and cytokine polarization: an overview. J Leukoc Biol 1995, 57:795-798.
134. Duthie M.S., Windish H.P., Fox C.B., et al. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011, 239:178-196.
135. Yewdell J.W., Haeryfar S.M. Understanding presentation of viral antigens to CD8+ T cells in: the key to rational vaccine design. Annu Rev Immunol 2005, 23:651-682.
136. Robinson H.L., Amara R.R. T cell vaccines for microbial infections. Nat Med 2005, 11(4 suppl):S25-S32.
137. Campbell D.J., Koch M.A. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 2011, 11:119-130.
138. Dannull J., Su Z., Rizzieri D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115:3623-3633.
139. Sallusto F., Lanzavecchia A., Araki K., et al. From vaccines to memory and back. Immunity 2010, 33:451-463.
140. Wherry E.J., Puorro K.A., Porgador A., et al. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J Immunol 1999, 163:3735-3745.
141. McShane H., Hill A. Prime-boost immunisation strategies for tuberculosis. Microbes Infect 2005, 7:962-967.
142. Dunachie S.J., Hill A.V. Prime-boost strategies for malaria vaccine development. J Exp Biol 2003, 206:3771-3779.
143. Malkevitch N.V., Robert-Guroff M. A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev Vaccines 2004, 3(4 suppl):S105-S117.
144. Lanzavecchia A., Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005, 17:326-332.
145. Huehn J., Siegmund K., Hamann A. Migration rules: functional properties of naive and effector/memory-like regulatory T cell subsets. Curr Top Microbiol Immunol 2005, 293:89-114.
146. Marsden V.S., Kappler J.W., Marrack P.C. Homeostasis of the memory T cell pool. Int Arch Allergy Immunol 2006, 139:63-74.
147. Combadiere B., Boissonnas A., Carcelain G., et al. Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 2004, 199:1585-1593.
148. Kennedy J.S., Frey S.E., Yan L., et al. Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis 2004, 190:1286-1294.
149. Hammarlund E., Lewis M.W., Hansen S.G., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003, 9:1131-1137.
150. Fine P.E. Non-specific "non-effects" of vaccination. BMJ 2004, 329:1297-1298.
151. Shann F. Heterologous immunity and the nonspecific effects of vaccines: a major medical advance?. Pediatr Infect Dis J 2004, 23:555-558.
152. Oldstone M.B. Molecular mimicry and immune-mediated diseases. FASEB J 1998, 12:1255-1265.
153. Di Genova G., Roddick J., McNicholl F., et al. Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine-specific. Blood 2006, 107:2806-2813.
154. Huang S.S., Platt R., Rifas-Shiman S.L., et al. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005, 116:e408-e413. [published correction appears in Pediatrics 117:593-594, 2006], doi:10.1542/peds.2004-2338.
155. Mayer S., Laumer M., Mackensen A., et al. Analysis of the immune response against tetanus toxoid: enumeration of specific T helper cells by the Elispot assay. Immunobiology 2002, 205:282-289.
156. Wraith D.C., Goldman M., Lambert P.H. Vaccination and autoimmune disease: what is the evidence?. Lancet 2003, 362:1659-1666.
157. Bacchetta R., Gregori S., Roncarolo M.G. CD4+ regulatory T cells: mechanisms of induction and effector function. Autoimmun Rev 2005, 4:491-496.
158. Vieira G.F., Chies J.A. Immunodominant viral peptides as determinants of cross-reactivity in the immune system: can we develop wide spectrum viral vaccines?. Med Hypotheses 2005, 65:873-879.
159. Cunha S.S., Rodrigues L.C., Pedrosa V., et al. Neonatal BCG protection against leprosy: a study in Manaus, Brazilian Amazon. Lepr Rev 2004, 75:357-366.
160. Hammarlund E., Lewis M.W., Carter S.V., et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med 2005, 11:1005-1011.
161. Gaglani M.J., Piedra P.A., Herschler G.B., et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 2004, 158:65-73.
162. Belshe R.B., Gruber W.C., Mendelman P.M., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181:1133-1137.
163. Offit P.A., Quarles J., Gerber M.A., et al. Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system?. Pediatrics 2002, 109:124-129.
164. Stowe J., Andrews N., Taylor B., et al. No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine. Vaccine 2009, 27:1422-1425.
165. Flanagan K.L., Klein S.L., Skakkebaek N.E., et al. Sex differences in the vaccine-specific and non-targeted effects of vaccines. Vaccine 2011, 29:2349-2354.
166. UNICEF The State of the World's Children 2009: Maternal and Newborn Health 2009, United Nations Children's Fund, New York, NY.
167. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007, 7:379-390.
168. Philbin V.J., Levy O. Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. Pediatr Res 2009, 65:98R-105R.
169. Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009, 9:185-194.
170. Kruschinski C., Zidan M., Debertin A.S., et al. Age-dependent development of the splenic marginal zone in human infants is associated with different causes of death. Hum Pathol 2004, 35:113-121.
171. Siegrist C.A. Neonatal and early life vaccinology. Vaccine 2001, 19:3331-3346.
172. Einhorn M.S., Weinberg G.A., Anderson E.L., et al. Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet 1986, 2:299-302.
173. Slack M.H., Schapira D., Thwaites R.J., et al. Responses to a fourth dose of Haemophilus influenzae type B conjugate vaccine in early life. Arch Dis Child Fetal Neonatal Ed 2004, 89:F269-F271.
174. Gans H.A., Arvin A.M., Galinus J., et al. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998, 280:527-532.
175. Vazquez M., LaRussa P.S., Gershon A.A., et al. Effectiveness over time of varicella vaccine. JAMA 2004, 291:851-855.
176. Siegrist C.A. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003, 21:3406-3412.
177. Pihlgren M., Tougne C., Bozzotti P., et al. Unresponsiveness to lymphoid-mediated signals at the neonatal follicular dendritic cell precursor level contributes to delayed germinal center induction and limitations of neonatal antibody responses to T-dependent antigens. J Immunol 2003, 170:2824-2832.
178. Belloni C., De Silvestri A., Tinelli C., et al. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 2003, 111:1042-1045.
179. Knuf M., Schmitt H.J., Wolter J., et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 2008, 152:655-660.e1.
180. Wood N., McIntyre P., Marshall H., et al. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J 2010, 29:209-215.
181. Halasa N.B., O'Shea A., Shi J.R., et al. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr 2008, 153:327-332.
182. Knuf M., Schmitt H.J., Jacquet J.M., et al. Booster vaccination after neonatal priming with acellular pertussis vaccine. J Pediatr 2010, 156:675-678.
183. Siegrist C.A. Blame vaccine interference, not neonatal immunization, for suboptimal responses after neonatal diphtheria, tetanus, and acellular pertussis immunization. J Pediatr 2008, 153:305-307.
184. Tiru M., Hallander H.O., Gustafsson L., et al. Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine 2000, 18:2295-2306.
185. Pihlgren M., Friedli M., Tougne C., et al. Reduced ability of neonatal and early-life bone marrow stromal cells to support plasmablast survival. J Immunol 2006, 176:165-172.
186. Longworth E., Borrow R., Goldblatt D., et al. Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 2002, 20:2592-2596.
187. Pichichero M.E., Voloshen T., Zajac D., et al. Avidity maturation of antibody to Haemophilus influenzae type b (Hib) after immunization with diphtheria-tetanus-acellular pertussis-hib-hepatitis B combined vaccine in infants. J Infect Dis 1999, 180:1390-1393.
188. Goldblatt D., Richmond P., Millard E., et al. The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. J Infect Dis 1999, 180:538-541.
189. Vekemans J., Ota M.O., Wang E.C., et al. T cell responses to vaccines in infants: defective IFNgamma production after oral polio vaccination. Clin Exp Immunol 2002, 127:495-498.
190. Ota M.O., Vekemans J., Schlegel-Haueter S.E., et al. Hepatitis B immunisation induces higher antibody and memory Th2 responses in new-borns than in adults. Vaccine 2004, 22:511-519.
191. Rowe J., Macaubas C., Monger T., et al. Heterogeneity in diphtheria-tetanus-acellular pertussis vaccine-specific cellular immunity during infancy: relationship to variations in the kinetics of postnatal maturation of systemic th1 function. J Infect Dis 2001, 184:80-88.
192. White O.J., Rowe J., Richmond P., et al. Th2-polarisation of cellular immune memory to neonatal pertussis vaccination. Vaccine 2010, 28:2648-2652.
193. Goriely S., Vincart B., Stordeur P., et al. Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J Immunol 2001, 166:2141-2146.
194. De Wit D., Olislagers V., Goriely S., et al. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. Blood 2004, 103:1030-1032.
195. Corbett N.P., Blimkie D., Ho K.C., et al. Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS One 2010, 5:e15041. doi:10.1371/journal.pone.0015041.
196. Haines C.J., Giffon T.D., Lu L.S., et al. Human CD4+ T cell recent thymic emigrants are identified by protein tyrosine kinase 7 and have reduced immune function. J Exp Med 2009, 206:275-285.
197. Mold J.E., Michaelsson J., Burt T.D., et al. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science 2008, 322:1562-1565.
198. Vekemans J., Amedei A., Ota M.O., et al. Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. Eur J Immunol 2001, 31:1531-1535.
199. Simister N.E. Placental transport of immunoglobulin G. Vaccine 2003, 21:3365-3369.
200. Albrecht P., Ennis F.A., Saltzman E.J., et al. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr 1977, 91:715-718.
201. Jelonek M.T., Maskrey J.L., Steimer K.S., et al. Maternal monoclonal antibody to the V3 loop alters specificity of the response to a human immunodeficiency virus vaccine. J Infect Dis 1996, 174:866-869.
202. Kurikka S., Olander R.M., Eskola J., et al. Passively acquired anti-tetanus and anti-Haemophilus antibodies and the response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infancy. Pediatr Infect Dis J 1996, 15:530-535.
203. Nohynek H., Gustafsson L., Capeding M.R., et al. Effect of transplacentally acquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b-tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants. Pediatr Infect Dis J 1999, 18:25-30.
204. Kim D., Huey D., Oglesbee M. Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies. Blood 2011, 117:6143-6151.
205. Dagan R., Amir J., Mijalovsky A., et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 2000, 19:1045-1052.
206. Dagan R., Ashkenazi S., Amir J., et al. High-dose inactivated hepatitis A vaccine (HD-HAV-VAC) in infants: comparison of response in the presence versus absence of maternally-derived antibodies (MatAb) 1998, San Diego, California.
207. Cutts F.T., Nyandu B., Markowitz L.E., et al. Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of medium- or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire. Vaccine 1994, 12:1311-1316.
208. Pabst H.F., Spady D.W., Carson M.M., et al. Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants. Vaccine 1999, 17:1910-1918.
209. Gans H.A., Maldonado Y., Yasukawa L.L., et al. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol 1999, 162:5569-5575.
210. Rowe J., Poolman J.T., Macaubas C., et al. Enhancement of vaccine-specific cellular immunity in infants by passively acquired maternal antibody. Vaccine 2004, 22:3986-3992.
211. PrabhuDas M., Adkins B., Gans H., et al. Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol 2011, 12:189-194.
212. LeMaoult J., Delassus S., Dyall R., et al. Clonal expansions of B lymphocytes in old mice. J Immunol 1997, 159:3866-3874.
213. Frasca D., Riley R.L., Blomberg B.B. Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin Immunol 2005, 17:378-384.
214. Murasko D.M., Bernstein E.D., Gardner E.M., et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002, 37:427-439.
215. Gardner E.M., Bernstein E.D., Dran S., et al. Characterization of antibody responses to annual influenza vaccination over four years in a healthy elderly population. Vaccine 2001, 19:4610-4617.
216. Hainz U., Jenewein B., Asch E., et al. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine 2005, 23:3232-3235.
217. Artz A.S., Ershler W.B., Longo D.L. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 2003, 16:308-318.
218. Gabay C., Bel M., Combescure C., et al. Impact of synthetic and biological disease-modifying antirheumatic drugs on antibody responses to the ASO3-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011, 63:1486-1496. doi:10.1002/art.30325.
219. Weksler M.E. Changes in the B-cell repertoire with age. Vaccine 2000, 18:1624-1628.
220. Romero-Steiner S., Musher D.M., Cetron M.S., et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999, 29:281-288.
221. Chen W.H., Kozlovsky B.F., Effros R.B., et al. Vaccination in the elderly: an immunological perspective. Trends Immunol 2009, 30:351-359.
222. Shi Y., Yamazaki T., Okubo Y., et al. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J Immunol 2005, 175:3262-3267.
223. Luscieti P., Hubschmid T., Cottier H., et al. Human lymph node morphology as a function of age and site. J Clin Pathol 1980, 33:454-461.
224. Lottenbach K.R., Mink C.M., Barenkamp S.J., et al. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect Immun 1999, 67:4935-4938.
225. Burns E.A., Lum L.G., Seigneuret M.C., et al. Decreased specific antibody synthesis in old adults: decreased potency of antigen-specific B cells with aging. Mech Ageing Dev 1990, 53:229-241.
226. Aydar Y., Balogh P., Tew J.G., et al. Follicular dendritic cells in aging, a "bottle-neck" in the humoral immune response. Ageing Res Rev 2004, 3:15-29.
227. Zheng B., Han S., Takahashi Y., et al. Immunosenescence and germinal center reaction. Immunol Rev 1997, 160:63-77.
228. Song H., Price P.W., Cerny J. Age-related changes in antibody repertoire: contribution from T cells. Immunol Rev 1997, 160:55-62.
229. Kang I., Hong M.S., Nolasco H., et al. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J Immunol 2004, 173:673-681.
230. Kovaiou R.D., Weiskirchner I., Keller M., et al. Age-related differences in phenotype and function of CD4+ T cells are due to a phenotypic shift from naive to memory effector CD4+ T cells. Int Immunol 2005, 17:1359-1366.
231. Deng Y., Jing Y., Campbell A.E., et al. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 2004, 172:3437-3446.